Why the study?
Does pulmonary 18F-FDG uptake correlate with disease severity and survival in treated patients with idiopathic pulmonary arterial hypertension?
Does pulmonary 18F-FDG uptake correlate with disease severity and survival in treated patients with idiopathic pulmonary arterial hypertension?
Pulmonary 18F-FDG uptake is low in treated IPAH patients and does not correlate with disease severity or survival, limiting its clinical utility as a biomarker in this population.
No takes yet. Share an insight, caveat, or question.
Lung 18F-FDG PET lacks biomarker utility in treated IPAH; leaves open its value in untreated or early disease.
Ruiter et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: